Saltar al contenido
Merck

920436

Sigma-Aldrich

NanoFabTx PEG-PLA drug formulation screening kit

for synthesis of PEGylated nanoparticles

Sinónimos:

Microfluidics, NanoFabTx reagent kit, Nanoformulation, Nanoparticle kit, PEG-PLA

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

UNSPSC Code:
12161503
NACRES:
NA.23

description

Kit components :
PEGPLA-L-M (919942-500mg)
PEGPLA-H-M (919934-500mg)
Stabilizer-Nano (907766-5g)

PEG-PLA drug formulation screening kit, for synthesis of PEGylated PLA nanoparticles

Quality Level

application(s)

advanced drug delivery

storage temp.

2-8°C

General description

NanoFabTx PEG-PLA drug formulation screening kit is a nanoformulation kit containing rationally selected PEGylated PLA polymers that have been used widely for controlled drug release of many different types of therapeutic molecules. The kit contains protocols for two different particle synthesis methods:
  • A Nanoprecipitation protocol to prepare drug-encapsulated nanoparticles in standard laboratory glassware.
  • A Microfluidics protocol using commercial platforms or syringe pumps.
The microfluidics protocol uses NanoFabTx device kits (911593), which provide all the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).

Application

NanoFabTx PEG-PLA drug formulation screening kit enables users to encapsulate a wide variety of therapeutic drug molecules in specifically sized, biodegradable, PEGylated PLA nanoparticles. By simplifying the chemistry and providing an easy-to-use toolkit with step-by-step instructions, our NanoFabTx nanoformulation screening kit helps researchers achieve reproducible synthesis of drug encapsulating nanoparticles with narrow size dispersity, eliminating the need for lengthy trial-and-error optimization. Suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery, PEG-PLA nanoparticles, made using the NanoFabTx PEG-PLA drug formulation screening kit, are designed for maximizing the encapsulation of hydrophobic drugs to minimize the time and expensive wasted reagents of synthetic optimization.

Features and Benefits

  • Includes tested protocols with step-by-step instructions for nanoprecipitation or microfluidics-based syntheses
  • Requires minimal laboratory setup
  • Optimized to achieve monodisperse, homogenously shaped, biodegradable, PEGylated PLA nanoparticles in any size between 60 and 100 nm
  • Formulated to maximize the encapsulation of hydrophobic drugs
  • Includes two different PEGylated PLAs

Legal Information

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

Storage Class

10 - Combustible liquids


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Sungmin Nam et al.
Biomaterials, 200, 15-24 (2019-02-12)
Hydrogels are commonly used as artificial extracellular matrices for 3D cell culture and for tissue engineering. Viscoelastic hydrogels with tunable stress relaxation have recently been developed, and stress relaxation in the hydrogels has been found to play a key role
S Freiberg et al.
International journal of pharmaceutics, 282(1-2), 1-18 (2004-09-01)
Polymer microspheres can be employed to deliver medication in a rate-controlled and sometimes targeted manner. Medication is released from a microsphere by drug leaching from the polymer or by degradation of the polymer matrix. Since the rate of drug release
C Thomasin et al.
Journal of pharmaceutical sciences, 87(3), 269-275 (1998-04-02)
Phase separation (frequently called coacervation) of poly(lactide) (PLA) and poly(lactide-co-glycolide) (PLGA) is a classical method for drug microencapsulation. Here, attempts have been made to describe this process in the light of thermodynamics. Different PLA/PLGAs were dissolved in either dichloromethane or
Robert F Pagels et al.
Journal of controlled release : official journal of the Controlled Release Society, 219, 519-535 (2015-09-12)
Biologically derived therapeutics, or biologics, are the most rapidly growing segment of the pharmaceutical marketplace. However, there are still unmet needs in improving the delivery of biologics. Injectable polymeric nanoparticles and microparticles capable of releasing proteins and peptides over time
Verónica Lassalle et al.
Macromolecular bioscience, 7(6), 767-783 (2007-06-02)
The controlled release of medicaments remains the most convenient way of drug delivery. Therefore, a wide variety of reports can be found in the open literature dealing with drug delivery systems. In particular, the use of nano- and microparticles devices

Artículos

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

Ver todo

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico